uBiome restructuring not affecting MEBO study

On September 4th, MEBO received an email from the Research and Collaborations Lead scientist, who has been providing us with ongoing support on the MEBO Clinical Trial, NCT03582826, Microbial Basis of Systemic Malodor and PATM Conditions, a research study funded by a uBiome research grant. In her email, she informs us that on the previous day, uBiome filed for Chapter 11 Bankruptcy protection. She further explains:

uBiome filed for Chapter 11 Bankruptcy protection. This a necessary step in our ongoing restructuring and will allow our business to move forward as a whole. I wanted to ensure you that business is currently continuing as normal, and our laboratory operations will continue.

We are dedicated to continuing our research partnerships as they are an essential element of the future of the company, and I want to emphasize that our support of your ongoing studies will not be affected.

https://www.cnbc.com/2019/09/04/ubiome-files-for-bankruptcy-five-months-after-fbi-raid.html

In addition, I asked the uBiome scientist why the new TMA results category was removed from each participant's personal online report, to which she replied:

I am so sorry that it has been removed, I know it was useful for you and the community.

In the last few weeks/months we have been updating Explorer to make sure what we are saying is scientifically valid and can stand up to scrutiny. I am not on the product team so I was not involved in the decision, but the decision to remove that was most likely based on what they felt was substantial scientific evidence to be able to report those results.

She added that she will mention it again to the product team when they make more updates.

At the present time, uBiome continues to offer the same Gut Explorer test used for the above mentioned MEBO clinical trial.

MEBO Dynamics of the Gut Microbiota 

in Idiopathic Malodor Production

This MEBO clinical trial is in its final stages of data analysis and will soon publish the conclusion. Meanwhile, the updates on findings by Irene Gabashvili, PhD., Principal Investigator, can be found in the following posts in the Aurametrix Blog:

1. Alloprevotella: September 4, 2019
2. Epulopiscium: August 19, 2019
3. Friends and Stars: August 14, 2019
4. PATM and TMAU: August 5, 2019
5. Feeding microbiomes: July 21, 2019
6. Blood type: June 2, 2019
7. First 41 results: November 21, 2018
8. Press Release: November 28, 2018
9. What we hope to learn: June 27, 2018
10. MEBO Microbiome Study: June 215, 2018
11. Microbes of anti-social odor: March 14, 2018
12. Crowdsourcing precision medicine: February 23, 2018

We are most grateful to uBiome for their very generous research grant and to Irene for her dedication and leadership in this research study.

María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
www.mebo.com.br/
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

---

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

---

A EURORDIS and NORD Member Organization